GlassScriptPhysician profile
Wanda V Mcmicheal
NPI 1619994316
$1,887.33
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $368 · 2021: $340 · 2022: $676 · 2023: $84.20 · 2024: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.26 | 2021-2024 | |
| Novo Nordisk INC | $203.20 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $191.90 | 2019-2022 | |
| Glaxosmithkline, LLC. | $176.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.69 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $106.71 | 2022-2023 | Rexulti |
| Allergan, INC. | $102.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $91.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.91 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $61.15 | 2019-2020 | |
| Lilly USA, LLC | $54.54 | 2022 | |
| Abbott Laboratories | $42.37 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.46 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $23.04 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.71 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.51 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.27 | 2022 | |
| Baxter Healthcare | $15.87 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $15.41 | 2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $13.23 | 2023 | Repatha |
| Esperion Therapeutics, INC. | $12.47 | 2021 | |
| Phadia US INC. | $12.33 | 2020 | |
| Pfizer INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Mcmicheal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.